FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387208945> ?p ?o ?g. }

• W4387208945 abstract "Hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) is the most frequently diagnosed metastatic breast cancer (mBC) subtype. Combinations of endocrine therapy (ET) with cyclin-dependent kinase 4/6 inhibitors (CDK4 & 6is) improve outcomes compared with ET alone. The efficacy and safety of abemaciclib among patients with HR+/HER2- mBC has been demonstrated in the MONARCH clinical trials; however, there is a paucity of real-world evidence, particularly in older patients.This retrospective cohort study analyzed the electronic medical record data/charts of adult patients with HR+/HER2- mBC receiving abemaciclib in US-based community oncology settings (1 September 2017 to 30 September 2019). Patients with other primary malignancies, clinical trial enrollment, and incomplete charts were excluded. Patient characteristics, treatment attributes and patterns, and real-world outcomes (clinical benefit rate [CBR] and stable disease among patients with response data available, time to chemotherapy [TTC], time to treatment discontinuation [TTD], and progression-free survival [PFS]) were summarized. Multivariable models evaluated the association between demographic/clinical characteristics and outcomes.Of the 448 final patients, 99% were female, with a median age of 67 years (25% were ≥ 75 years) and median follow-up of 11 months; most (60%) initiated abemaciclib within 2 years of mBC diagnosis. Patients received a median of 1 (P25 = 0, P75 = 3) prior line of therapy for mBC before abemaciclib, including other CDK4 & 6is (48%) and prior chemotherapy (31%); most (57%) had visceral disease. The CBR for the overall population was 53%, with 48% achieving stable disease. The median TTC was not reached; median TTD was 249 days (95% confidence interval [CI]: 202, 304). The median PFS was 329 days (95% CI 266, 386). The discontinuation rate of abemaciclib owing to adverse events (30%) trended higher with age (years) (P = 0.027): 18-49 (n = 42; 19%), 50-64 (n = 155; 25%), 65-74 (n = 138; 32%), 75-84 (n = 82; 37%), ≥ 85 (n = 31; 49%); only 23% of patients overall had a dose hold or reduction prior to discontinuation.These patients were older than those in the MONARCH studies with substantial visceral disease, and prior chemotherapy and CDK4 & 6i use. Discontinuation rates were higher than in previous real-world studies (11.9%), highlighting the need for proactive management to optimize outcomes, particularly in older patients with mBC." @default.
• W4387208945 created "2023-09-30" @default.
• W4387208945 creator A5002318079 @default.
• W4387208945 creator A5005185722 @default.
• W4387208945 creator A5007290313 @default.
• W4387208945 creator A5009694312 @default.
• W4387208945 creator A5026174766 @default.
• W4387208945 creator A5028712710 @default.
• W4387208945 creator A5043605449 @default.
• W4387208945 creator A5047612420 @default.
• W4387208945 creator A5057484166 @default.
• W4387208945 creator A5083092373 @default.
• W4387208945 creator A5086108457 @default.
• W4387208945 date "2023-09-29" @default.
• W4387208945 modified "2023-10-09" @default.
• W4387208945 title "Real-World Analysis of Clinical and Demographic Characteristics, Treatment Patterns, and Outcomes in Predominantly Older Patients with HR+/HER2− Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical Practice" @default.
• W4387208945 cites W1971185870 @default.
• W4387208945 cites W1975879668 @default.
• W4387208945 cites W2070780645 @default.
• W4387208945 cites W2112646145 @default.
• W4387208945 cites W2116144791 @default.
• W4387208945 cites W2140056658 @default.
• W4387208945 cites W2159427817 @default.
• W4387208945 cites W2162383121 @default.
• W4387208945 cites W2165999332 @default.
• W4387208945 cites W2166463482 @default.
• W4387208945 cites W2204808283 @default.
• W4387208945 cites W2263556989 @default.
• W4387208945 cites W2290950904 @default.
• W4387208945 cites W2552099557 @default.
• W4387208945 cites W2560635244 @default.
• W4387208945 cites W2614466076 @default.
• W4387208945 cites W2617437931 @default.
• W4387208945 cites W2620993107 @default.
• W4387208945 cites W2763875663 @default.
• W4387208945 cites W2788603587 @default.
• W4387208945 cites W2802776309 @default.
• W4387208945 cites W2804105316 @default.
• W4387208945 cites W2805575723 @default.
• W4387208945 cites W2901884329 @default.
• W4387208945 cites W2910972034 @default.
• W4387208945 cites W2950839322 @default.
• W4387208945 cites W2975749949 @default.
• W4387208945 cites W2976415870 @default.
• W4387208945 cites W2977565884 @default.
• W4387208945 cites W2982150569 @default.
• W4387208945 cites W3027235130 @default.
• W4387208945 cites W3030172639 @default.
• W4387208945 cites W3049370161 @default.
• W4387208945 cites W3087561595 @default.
• W4387208945 cites W3091199432 @default.
• W4387208945 cites W3091902443 @default.
• W4387208945 cites W3115380088 @default.
• W4387208945 cites W3120214437 @default.
• W4387208945 cites W3132856650 @default.
• W4387208945 cites W3157645496 @default.
• W4387208945 cites W3161555469 @default.
• W4387208945 cites W3207557929 @default.
• W4387208945 cites W4206666777 @default.
• W4387208945 cites W4206841660 @default.
• W4387208945 cites W4234749243 @default.
• W4387208945 doi "https://doi.org/10.1007/s40801-023-00391-1" @default.
• W4387208945 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37775689" @default.
• W4387208945 hasPublicationYear "2023" @default.
• W4387208945 type Work @default.
• W4387208945 citedByCount "0" @default.
• W4387208945 crossrefType "journal-article" @default.
• W4387208945 hasAuthorship W4387208945A5002318079 @default.
• W4387208945 hasAuthorship W4387208945A5005185722 @default.
• W4387208945 hasAuthorship W4387208945A5007290313 @default.
• W4387208945 hasAuthorship W4387208945A5009694312 @default.
• W4387208945 hasAuthorship W4387208945A5026174766 @default.
• W4387208945 hasAuthorship W4387208945A5028712710 @default.
• W4387208945 hasAuthorship W4387208945A5043605449 @default.
• W4387208945 hasAuthorship W4387208945A5047612420 @default.
• W4387208945 hasAuthorship W4387208945A5057484166 @default.
• W4387208945 hasAuthorship W4387208945A5083092373 @default.
• W4387208945 hasAuthorship W4387208945A5086108457 @default.
• W4387208945 hasBestOaLocation W43872089451 @default.
• W4387208945 hasConcept C121608353 @default.
• W4387208945 hasConcept C126322002 @default.
• W4387208945 hasConcept C143998085 @default.
• W4387208945 hasConcept C195910791 @default.
• W4387208945 hasConcept C2775930923 @default.
• W4387208945 hasConcept C2778715236 @default.
• W4387208945 hasConcept C2908647359 @default.
• W4387208945 hasConcept C530470458 @default.
• W4387208945 hasConcept C535046627 @default.
• W4387208945 hasConcept C71924100 @default.
• W4387208945 hasConcept C72563966 @default.
• W4387208945 hasConcept C99454951 @default.
• W4387208945 hasConceptScore W4387208945C121608353 @default.
• W4387208945 hasConceptScore W4387208945C126322002 @default.
• W4387208945 hasConceptScore W4387208945C143998085 @default.
• W4387208945 hasConceptScore W4387208945C195910791 @default.
• W4387208945 hasConceptScore W4387208945C2775930923 @default.
• W4387208945 hasConceptScore W4387208945C2778715236 @default.
• W4387208945 hasConceptScore W4387208945C2908647359 @default.
• W4387208945 hasConceptScore W4387208945C530470458 @default.
• W4387208945 hasConceptScore W4387208945C535046627 @default.

• next